<drug type="biotech" created="2005-06-13" updated="2021-01-01">
  <drugbank-id primary="true">DB00012</drugbank-id>
  <drugbank-id>BTD00032</drugbank-id>
  <drugbank-id>BIOD00032</drugbank-id>
  <name>Darbepoetin alfa</name>
  <description>Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.</description>
  <cas-number>209810-58-2</cas-number>
  <unii>15UQ94PT4P</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of anemia (from renal transplants or certain HIV treatment)</indication>
  <pharmacodynamics>Darbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.</pharmacodynamics>
  <mechanism-of-action>Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with&#13;
progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Darbepoetin</synonym>
    <synonym language="english" coder="">Darbepoetin alfa,recombinant</synonym>
    <synonym language="spanish" coder="">Darbepoetina alfa</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/001</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/002</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/003</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/004</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/005</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/006</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/007</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/008</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/009</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/010</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/011</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/012</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/013</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/014</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/015</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/016</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/017</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/018</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/019</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/020</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/021</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/022</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/031</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/032</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/033</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/034</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/035</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/036</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/037</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/038</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/039</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/040</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/041</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/042</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/043</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/044</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/045</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/046</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/047</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/048</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/049</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/050</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/051</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/052</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/053</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/054</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/055</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/056</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/057</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/058</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/059</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/060</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/061</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/062</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/063</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/064</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/065</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/066</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/067</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/068</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/069</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/070</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/071</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/072</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/073</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/074</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/075</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/076</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/077</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/078</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/079</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/080</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/081</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/082</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/083</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/084</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/085</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/086</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/087</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/088</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/089</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/090</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/091</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/092</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/093</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/094</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/095</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/096</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/097</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/098</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/099</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/100</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/101</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/102</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/103</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/104</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/105</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/106</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/107</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/108</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/109</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/110</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000332</ema-product-code>
      <ema-ma-number>EU/1/01/185/111</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-13</started-marketing-on>
      <ended-marketing-on>2013-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 ug/0.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5429</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-20</started-marketing-on>
      <ended-marketing-on>2013-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 ug/0.6mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5867</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-20</started-marketing-on>
      <ended-marketing-on>2013-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-01</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>200 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-19</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>300 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-01</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>25 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-01</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>40 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-01</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>60 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-01</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>100 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-01</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>150 ug/0.75mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-044</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-23</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 ug/0.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-046</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-23</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 ug/0.6mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-02-10</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-039</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-23</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 ug/0.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-23</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/0.5mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-043</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-01</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 ug/0.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 ug/0.42mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 ug/0.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 ug/0.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/0.5mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-094</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 ug/0.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 ug/0.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-096</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 ug/0.6mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-25</started-marketing-on>
      <ended-marketing-on>2010-02-16</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-02-14</started-marketing-on>
      <ended-marketing-on>2008-11-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 ug/.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-058</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-02-10</started-marketing-on>
      <ended-marketing-on>2009-03-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 ug/0.42mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>150 ug/0.75mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-098</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 ug/0.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>300 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>25 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>60 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-028</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 ug/0.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 ug/0.6mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 ug/1mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-057</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 ug/0.42mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 ug/0.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 ug/0.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-025</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/0.5mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>AMGEN INC</labeller>
      <ndc-id/>
      <ndc-product-code>55513-027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 ug/0.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391740</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391759</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391767</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391775</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391783</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391791</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391805</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391821</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392313</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>25 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392321</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392348</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392356</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392364</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246354</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>25 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246353</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>15 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246356</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>60 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246359</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>325 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391732</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391813</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391848</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246355</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246357</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-20</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246358</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246360</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/001</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/002</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/003</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/004</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/005</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/006</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/007</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/008</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/009</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/010</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/011</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/012</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/013</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/014</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/015</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/016</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/017</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/018</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/019</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/020</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/021</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/022</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/023</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/024</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/025</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/026</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/027</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/028</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/029</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/030</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/031</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/032</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/033</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/034</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/035</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/036</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/037</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/038</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/039</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/040</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/041</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/042</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/043</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/044</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/045</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/046</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/047</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/048</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/049</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/050</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/051</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/052</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/053</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/054</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/055</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/056</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/057</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/058</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>15 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/059</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/060</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/061</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/062</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/063</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/064</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>80 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/065</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/066</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/067</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/068</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/069</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/070</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/071</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/072</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nespo</name>
      <labeller>Dompé Biotec S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000333</ema-product-code>
      <ema-ma-number>EU/1/01/184/073</ema-ma-number>
      <started-marketing-on>2001-06-08</started-marketing-on>
      <ended-marketing-on>2008-12-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>130 μg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amgen Inc.</name>
      <url>http://www.amgen.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Amgen Inc.</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Aranesp 25 mcg/ml vial</description>
      <cost currency="USD">156.36</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 25 mcg/ml vial</description>
      <cost currency="USD">162.61</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Aranesp 40 mcg/ml vial</description>
      <cost currency="USD">250.2</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp 60 mcg/ml vial</description>
      <cost currency="USD">375.3</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 60 mcg/ml vial</description>
      <cost currency="USD">390.31</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Aranesp 100 mcg/ml vial</description>
      <cost currency="USD">625.44</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp 200 mcg/ml vial</description>
      <cost currency="USD">1250.88</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp 300 mcg/ml vial</description>
      <cost currency="USD">1876.32</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 300 mcg/ml vial</description>
      <cost currency="USD">1951.37</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 100 mcg/0.5ml Solution (1 Box = Four 0.5ml Syringes)</description>
      <cost currency="USD">2601.83</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 100 mcg/ml Solution Four 1ml Vials Per Box</description>
      <cost currency="USD">2601.83</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 150 mcg/0.75ml Solution (1 Box = Four 0.75ml Vials)</description>
      <cost currency="USD">3902.75</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antianemic Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Erythropoiesis-Stimulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Hematinics</category>
      <mesh-id>D006397</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Increased Erythroid Cell Production</category>
      <mesh-id/>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>10 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>100 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>130 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>15 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>150 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>20 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>25 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>30 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>300 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>40 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>50 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>500 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>60 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>80 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 ug/0.4mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 ug/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>130 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>15 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 ug/0.4mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 ug/0.42mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 ug/0.6mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 ug/0.4mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 ug/.4mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>50 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 ug/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>80 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>10 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>100 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>15 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>150 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>20 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>30 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>300 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>40 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>50 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>500 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>60 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>80 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>10 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>130 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>15 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>150 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>20 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>30 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>40 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>50 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>500 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>60 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>80 μg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>15 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 ug/0.75mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>325 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 ug/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 mcg/0.4ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>10 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 UG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>130 UG</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 mcg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>150 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>150 UG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>15 UG</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>20 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>20 UG</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30 mcg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>30 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>300 UG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>30 UG</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 mcg/0.4ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>40 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>40 UG</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>50 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>50 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>500 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>500 UG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>50 UG</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 mcg/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>60 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>60 UG</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>80 mcg/0.4ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>80 MIKROGRAMM</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>80 UG</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>50 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 cg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>80 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 mcg</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>120 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>20 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>30 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>40 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>60 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>10 mcg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>120 mcg/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>120 mcg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>15 mcg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>20 mcg/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>20 mcg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>30 mcg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>30 mcg/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>40 mcg/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>40 mcg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>60 mcg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>10 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>120 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>180 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>20 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>30 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>40 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>60 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>10 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>100 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>15 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>150 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>20 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>25 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>30 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>300 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>40 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>50 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>500 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>60 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>80 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>10 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>15 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>150 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>20 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>30 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>40 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>50 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>500 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>60 MCG</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>80 MCG</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B03XA02">
      <level code="B03XA">Other antianemic preparations</level>
      <level code="B03X">OTHER ANTIANEMIC PREPARATIONS</level>
      <level code="B03">ANTIANEMIC PREPARATIONS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents>
    <patent>
      <number>2165694</number>
      <country>Canada</country>
      <approved>2003-03-18</approved>
      <expires>2010-10-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2147124</number>
      <country>Canada</country>
      <approved>2002-11-05</approved>
      <expires>2014-08-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00002</drugbank-id>
      <name>Cetuximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00004</drugbank-id>
      <name>Denileukin diftitox</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00023</drugbank-id>
      <name>Asparaginase Escherichia coli</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Asparaginase Escherichia coli.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trastuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Masoprocol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00236</drugbank-id>
      <name>Pipobroman</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pipobroman.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Chlorotrianisene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pamidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bleomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Floxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00385</drugbank-id>
      <name>Valrubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valrubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Flutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alitretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nilutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00707</drugbank-id>
      <name>Porfimer sodium</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Porfimer sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00791</drugbank-id>
      <name>Uracil mustard</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Uracil mustard.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00855</drugbank-id>
      <name>Aminolevulinic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aminolevulinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Testolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00947</drugbank-id>
      <name>Fulvestrant</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fulvestrant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00990</drugbank-id>
      <name>Exemestane</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Exemestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Letrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trimetrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Anastrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01269</drugbank-id>
      <name>Panitumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Panitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 8-azaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01873</drugbank-id>
      <name>Epothilone D</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epothilone D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01933</drugbank-id>
      <name>7-Hydroxystaurosporine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 7-Hydroxystaurosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02109</drugbank-id>
      <name>Hadacidin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hadacidin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02342</drugbank-id>
      <name>2-Methoxyestradiol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 2-Methoxyestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02424</drugbank-id>
      <name>Geldanamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Geldanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02640</drugbank-id>
      <name>Fumagillin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fumagillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03010</drugbank-id>
      <name>Patupilone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Patupilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03172</drugbank-id>
      <name>Tubercidin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tubercidin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03459</drugbank-id>
      <name>Sparfosic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sparfosic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03496</drugbank-id>
      <name>Alvocidib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alvocidib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03509</drugbank-id>
      <name>2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03695</drugbank-id>
      <name>Piritrexim</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Piritrexim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rhodamine 6G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03880</drugbank-id>
      <name>Batimastat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Batimastat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03946</drugbank-id>
      <name>3,4-Dihydroxybenzoic Acid</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 3,4-Dihydroxybenzoic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04106</drugbank-id>
      <name>Fotemustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fotemustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04222</drugbank-id>
      <name>Sparsomycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sparsomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04253</drugbank-id>
      <name>Tretazicar</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tretazicar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04258</drugbank-id>
      <name>Seocalcitol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Seocalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04331</drugbank-id>
      <name>Monastrol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Monastrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04440</drugbank-id>
      <name>Nebularine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nebularine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04468</drugbank-id>
      <name>Afimoxifene</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Afimoxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04655</drugbank-id>
      <name>Metoprine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Metoprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Camptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04786</drugbank-id>
      <name>Suramin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Suramin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Urethane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04849</drugbank-id>
      <name>Cediranib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cediranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04858</drugbank-id>
      <name>Tirapazamine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tirapazamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04866</drugbank-id>
      <name>Halofuginone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Halofuginone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04894</drugbank-id>
      <name>Vapreotide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vapreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04900</drugbank-id>
      <name>Thymalfasin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Thymalfasin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04901</drugbank-id>
      <name>Galiximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Galiximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04907</drugbank-id>
      <name>Sitimagene ceradenovec</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sitimagene ceradenovec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04950</drugbank-id>
      <name>Ranpirnase</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ranpirnase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04958</drugbank-id>
      <name>Epratuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epratuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04960</drugbank-id>
      <name>Tipifarnib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tipifarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04961</drugbank-id>
      <name>Troxacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Troxacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04964</drugbank-id>
      <name>Oregovomab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oregovomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04975</drugbank-id>
      <name>Banoxantrone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Banoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04977</drugbank-id>
      <name>Plitidepsin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plitidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04996</drugbank-id>
      <name>Satraplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Satraplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05022</drugbank-id>
      <name>Amonafide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Amonafide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05076</drugbank-id>
      <name>Fenretinide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fenretinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05088</drugbank-id>
      <name>Tetrathiomolybdate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tetrathiomolybdate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05097</drugbank-id>
      <name>Labetuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Labetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05129</drugbank-id>
      <name>Elsamitrucin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Elsamitrucin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05136</drugbank-id>
      <name>Bavituximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bavituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05223</drugbank-id>
      <name>Pracinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pracinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cobimetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05265</drugbank-id>
      <name>Ecabet</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ecabet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rindopepimut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05424</drugbank-id>
      <name>Canertinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Canertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05428</drugbank-id>
      <name>Motexafin gadolinium</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Motexafin gadolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05482</drugbank-id>
      <name>7-ethyl-10-hydroxycamptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 7-ethyl-10-hydroxycamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05524</drugbank-id>
      <name>Pelitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pelitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05540</drugbank-id>
      <name>Alanosine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alanosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05578</drugbank-id>
      <name>Ramucirumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ramucirumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05595</drugbank-id>
      <name>Farletuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Farletuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05656</drugbank-id>
      <name>Veltuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Veltuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05668</drugbank-id>
      <name>Palifosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Palifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05697</drugbank-id>
      <name>AP 12009</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with AP 12009.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05779</drugbank-id>
      <name>Oglufanide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oglufanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05786</drugbank-id>
      <name>Irofulven</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Irofulven.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Inotuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05903</drugbank-id>
      <name>KOS-1584</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KOS-1584.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05916</drugbank-id>
      <name>CT-011</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CT-011.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05974</drugbank-id>
      <name>Transcrocetinate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Transcrocetinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05996</drugbank-id>
      <name>Glembatumumab vedotin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Glembatumumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06013</drugbank-id>
      <name>Aldoxorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aldoxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06021</drugbank-id>
      <name>AV-412</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with AV-412.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06040</drugbank-id>
      <name>Filanesib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Filanesib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06043</drugbank-id>
      <name>Olaratumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olaratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06159</drugbank-id>
      <name>Rubitecan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rubitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06163</drugbank-id>
      <name>Plevitrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plevitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06171</drugbank-id>
      <name>Paclitaxel trevatide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel trevatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06181</drugbank-id>
      <name>IMO-2055</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with IMO-2055.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ipilimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06192</drugbank-id>
      <name>Nimotuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nimotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06193</drugbank-id>
      <name>Pixantrone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pixantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06195</drugbank-id>
      <name>Seliciclib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Seliciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06199</drugbank-id>
      <name>Atrasentan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Atrasentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06233</drugbank-id>
      <name>Ridaforolimus</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ridaforolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>Exisulind</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Exisulind.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06263</drugbank-id>
      <name>Amrubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Amrubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06266</drugbank-id>
      <name>Lonidamine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lonidamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06272</drugbank-id>
      <name>Maxacalcitol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Maxacalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06317</drugbank-id>
      <name>Elotuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Elotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06334</drugbank-id>
      <name>Tucidinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tucidinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06365</drugbank-id>
      <name>Sapacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sapacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06366</drugbank-id>
      <name>Pertuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pertuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>Annamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Annamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06423</drugbank-id>
      <name>Endostatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Endostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06433</drugbank-id>
      <name>Tezacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tezacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06436</drugbank-id>
      <name>Semaxanib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Semaxanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Diethylnorspermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06461</drugbank-id>
      <name>Squalamine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Squalamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06478</drugbank-id>
      <name>Porfiromycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Porfiromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06517</drugbank-id>
      <name>MLN576</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with MLN576.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06607</drugbank-id>
      <name>Catumaxomab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Catumaxomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Axitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Volociximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06650</drugbank-id>
      <name>Ofatumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ofatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Degarelix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methyltestosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Buserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06748</drugbank-id>
      <name>Ginsenoside C</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ginsenoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06810</drugbank-id>
      <name>Plicamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plicamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triptorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07232</drugbank-id>
      <name>Veliparib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Veliparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hexestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08313</drugbank-id>
      <name>Nocodazole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nocodazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Puromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08486</drugbank-id>
      <name>Efaproxiral</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Efaproxiral.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08633</drugbank-id>
      <name>TNP-470</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with TNP-470.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vismodegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabozantinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08886</drugbank-id>
      <name>Asparaginase Erwinia chrysanthemi</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Formestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trametinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08913</drugbank-id>
      <name>Radium Ra 223 dichloride</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Radium Ra 223 dichloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Afatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09010</drugbank-id>
      <name>Carmofur</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carmofur.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09031</drugbank-id>
      <name>Miltefosine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Miltefosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09035</drugbank-id>
      <name>Nivolumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nivolumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09037</drugbank-id>
      <name>Pembrolizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pembrolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09143</drugbank-id>
      <name>Sonidegib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sonidegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tegafur.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09274</drugbank-id>
      <name>Artesunate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Artesunate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09298</drugbank-id>
      <name>Silibinin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Silibinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09331</drugbank-id>
      <name>Daratumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daratumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09559</drugbank-id>
      <name>Necitumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ixazomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11366</drugbank-id>
      <name>Roquinimex</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Roquinimex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11526</drugbank-id>
      <name>Masitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Masitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11595</drugbank-id>
      <name>Atezolizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Atezolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11617</drugbank-id>
      <name>Aclarubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aclarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11618</drugbank-id>
      <name>Zorubicin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Zorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11630</drugbank-id>
      <name>Temoporfin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Temoporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11646</drugbank-id>
      <name>Conatumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Conatumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11651</drugbank-id>
      <name>Dactolisib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dactolisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11662</drugbank-id>
      <name>Rabusertib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rabusertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11669</drugbank-id>
      <name>Ortataxel</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ortataxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11678</drugbank-id>
      <name>Treosulfan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Treosulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11688</drugbank-id>
      <name>2-chloroethyl-3-sarcosinamide-1-nitrosourea</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 2-chloroethyl-3-sarcosinamide-1-nitrosourea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11694</drugbank-id>
      <name>Ilorasertib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ilorasertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11714</drugbank-id>
      <name>Durvalumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Durvalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11716</drugbank-id>
      <name>Misonidazole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Misonidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11717</drugbank-id>
      <name>Epacadostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epacadostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11718</drugbank-id>
      <name>Encorafenib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Encorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11727</drugbank-id>
      <name>Endostar</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Endostar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11737</drugbank-id>
      <name>Icotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Icotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11752</drugbank-id>
      <name>Bryostatin 1</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bryostatin 1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talazoparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11771</drugbank-id>
      <name>Tremelimumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tremelimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11793</drugbank-id>
      <name>Niraparib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Niraparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11795</drugbank-id>
      <name>GSK-2636771</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with GSK-2636771.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11800</drugbank-id>
      <name>Tivozanib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tivozanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11805</drugbank-id>
      <name>Saracatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Saracatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11812</drugbank-id>
      <name>Talaporfin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talaporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11830</drugbank-id>
      <name>Mocetinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mocetinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11832</drugbank-id>
      <name>Crenolanib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Crenolanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11841</drugbank-id>
      <name>Entinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Entinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11880</drugbank-id>
      <name>Acridine Carboxamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Acridine Carboxamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11886</drugbank-id>
      <name>Infigratinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Infigratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11891</drugbank-id>
      <name>CUDC-907</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CUDC-907.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11894</drugbank-id>
      <name>Efatutazone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Efatutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11907</drugbank-id>
      <name>Rociletinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rociletinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11918</drugbank-id>
      <name>Guadecitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Guadecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 6-O-benzylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11945</drugbank-id>
      <name>Avelumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Avelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Binimetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11972</drugbank-id>
      <name>Rilotumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rilotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11973</drugbank-id>
      <name>Tesevatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11999</drugbank-id>
      <name>Vosaroxin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vosaroxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Abemaciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alpelisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12028</drugbank-id>
      <name>Broxuridine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Broxuridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12036</drugbank-id>
      <name>Naquotinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Naquotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12056</drugbank-id>
      <name>Trebananib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trebananib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12081</drugbank-id>
      <name>Anecortave</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Anecortave.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12082</drugbank-id>
      <name>Vesnarinone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vesnarinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12083</drugbank-id>
      <name>Mafosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mafosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12085</drugbank-id>
      <name>LCL-161</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with LCL-161.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12108</drugbank-id>
      <name>Taselisib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Taselisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12124</drugbank-id>
      <name>Namitecan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Namitecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lorlatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gilteritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12142</drugbank-id>
      <name>Duligotuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Duligotuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12146</drugbank-id>
      <name>Rigosertib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rigosertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12156</drugbank-id>
      <name>Cordycepin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cordycepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12174</drugbank-id>
      <name>CUDC-101</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CUDC-101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12182</drugbank-id>
      <name>Binetrakin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Binetrakin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12185</drugbank-id>
      <name>Exatecan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Exatecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12202</drugbank-id>
      <name>Zalutumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Zalutumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12222</drugbank-id>
      <name>Lurtotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lurtotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12232</drugbank-id>
      <name>KRN-7000</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KRN-7000.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12257</drugbank-id>
      <name>Platinum</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Platinum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12259</drugbank-id>
      <name>CG-200745</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CG-200745.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12266</drugbank-id>
      <name>Epofolate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epofolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12279</drugbank-id>
      <name>OBP-801</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with OBP-801.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12340</drugbank-id>
      <name>Navitoclax</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Navitoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12352</drugbank-id>
      <name>Bizelesin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bizelesin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12376</drugbank-id>
      <name>Ricolinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ricolinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12379</drugbank-id>
      <name>Indirubin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Indirubin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12381</drugbank-id>
      <name>Merestinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Merestinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12382</drugbank-id>
      <name>R-306465</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with R-306465.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12385</drugbank-id>
      <name>10-hydroxycamptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 10-hydroxycamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12391</drugbank-id>
      <name>Sagopilone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sagopilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12422</drugbank-id>
      <name>Sulforaphane</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sulforaphane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12459</drugbank-id>
      <name>Belotecan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Belotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12473</drugbank-id>
      <name>Taurolidine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Taurolidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Copanlisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12498</drugbank-id>
      <name>Mogamulizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mogamulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12515</drugbank-id>
      <name>9-aminocamptothecin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 9-aminocamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12525</drugbank-id>
      <name>Molgramostim</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Molgramostim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12539</drugbank-id>
      <name>Oltipraz</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oltipraz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12549</drugbank-id>
      <name>Pyrazoloacridine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pyrazoloacridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12565</drugbank-id>
      <name>Abexinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Abexinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12577</drugbank-id>
      <name>Fosbretabulin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fosbretabulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12589</drugbank-id>
      <name>Dacetuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dacetuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12593</drugbank-id>
      <name>Apaziquone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Apaziquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12596</drugbank-id>
      <name>Combretastatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Combretastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12637</drugbank-id>
      <name>Onapristone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Onapristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12638</drugbank-id>
      <name>PU-H71</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with PU-H71.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12645</drugbank-id>
      <name>Givinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Givinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12671</drugbank-id>
      <name>Beloranib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Beloranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12677</drugbank-id>
      <name>Soblidotin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Soblidotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12681</drugbank-id>
      <name>Salirasib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Salirasib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12688</drugbank-id>
      <name>Moxetumomab Pasudotox</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Moxetumomab Pasudotox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12695</drugbank-id>
      <name>Phenethyl Isothiocyanate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Phenethyl Isothiocyanate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12697</drugbank-id>
      <name>Methylselenocysteine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methylselenocysteine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12701</drugbank-id>
      <name>Intetumumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Intetumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12730</drugbank-id>
      <name>Dolastatin 10</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dolastatin 10.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12736</drugbank-id>
      <name>Etanidazole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etanidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12769</drugbank-id>
      <name>Lometrexol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lometrexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12797</drugbank-id>
      <name>Ecromeximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ecromeximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12832</drugbank-id>
      <name>Prednimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12870</drugbank-id>
      <name>Buthionine Sulfoximine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Buthionine Sulfoximine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12873</drugbank-id>
      <name>Dianhydrogalactitol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dianhydrogalactitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12881</drugbank-id>
      <name>Indole-3-carbinol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Indole-3-carbinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12901</drugbank-id>
      <name>Fiacitabine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fiacitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12912</drugbank-id>
      <name>Nolatrexed</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nolatrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12916</drugbank-id>
      <name>Mitolactol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitolactol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12920</drugbank-id>
      <name>Pinometostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pinometostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12948</drugbank-id>
      <name>Didox</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Didox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12967</drugbank-id>
      <name>Mitoguazone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitoguazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pexidartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12987</drugbank-id>
      <name>Penclomedine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Penclomedine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13005</drugbank-id>
      <name>Rebastinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rebastinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13046</drugbank-id>
      <name>Tocladesine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tocladesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13066</drugbank-id>
      <name>Liarozole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Liarozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13069</drugbank-id>
      <name>Nimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13104</drugbank-id>
      <name>X-396</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with X-396.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13128</drugbank-id>
      <name>Sizofiran</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sizofiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nedaplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13164</drugbank-id>
      <name>Olmutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olmutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13182</drugbank-id>
      <name>Daidzein</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daidzein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13243</drugbank-id>
      <name>Tiazofurine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tiazofurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13304</drugbank-id>
      <name>Triaziquone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triaziquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13318</drugbank-id>
      <name>Demecolcine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Demecolcine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13334</drugbank-id>
      <name>Mannosulfan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mannosulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13339</drugbank-id>
      <name>Etoglucid</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etoglucid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13375</drugbank-id>
      <name>Edrecolomab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Edrecolomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13480</drugbank-id>
      <name>Lentinan</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lentinan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13543</drugbank-id>
      <name>Mitobronitol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitobronitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13647</drugbank-id>
      <name>Semustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Semustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13677</drugbank-id>
      <name>Carboquone</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13767</drugbank-id>
      <name>Vorozole</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vorozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13809</drugbank-id>
      <name>Paclitaxel poliglumex</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel poliglumex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13811</drugbank-id>
      <name>Oblimersen</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oblimersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13832</drugbank-id>
      <name>Ranimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ranimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13877</drugbank-id>
      <name>Iniparib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Iniparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13896</drugbank-id>
      <name>Talimogene laherparepvec</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talimogene laherparepvec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13912</drugbank-id>
      <name>Coumermycin A1</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Coumermycin A1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13916</drugbank-id>
      <name>Toyocamycin</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Toyocamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14031</drugbank-id>
      <name>Tretamine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14067</drugbank-id>
      <name>Dofequidar</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dofequidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14680</drugbank-id>
      <name>Combretastatin A4</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Combretastatin A4.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14707</drugbank-id>
      <name>Cemiplimab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cemiplimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Larotrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14731</drugbank-id>
      <name>Tagraxofusp</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tagraxofusp.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14765</drugbank-id>
      <name>Rivoceranib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rivoceranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14792</drugbank-id>
      <name>AZD-5991</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with AZD-5991.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14844</drugbank-id>
      <name>ONC-201</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with ONC-201.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14860</drugbank-id>
      <name>Ensartinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ensartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14865</drugbank-id>
      <name>Human interleukin-2</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Human interleukin-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14877</drugbank-id>
      <name>Lintuzumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lintuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14947</drugbank-id>
      <name>Bermekimab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bermekimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14951</drugbank-id>
      <name>Etirinotecan pegol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etirinotecan pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15035</drugbank-id>
      <name>Zanubrutinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Zanubrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15057</drugbank-id>
      <name>NUC-1031</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with NUC-1031.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15157</drugbank-id>
      <name>Voruciclib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Voruciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15215</drugbank-id>
      <name>KRN-5500</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KRN-5500.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15289</drugbank-id>
      <name>Perillyl alcohol</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Perillyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15321</drugbank-id>
      <name>Tefinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tefinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Biochanin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15351</drugbank-id>
      <name>Dihematoporphyrin ether</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dihematoporphyrin ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15366</drugbank-id>
      <name>SOR-C13</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with SOR-C13.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15383</drugbank-id>
      <name>Pidilizumab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pidilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15419</drugbank-id>
      <name>Nanatinostat</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nanatinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15466</drugbank-id>
      <name>Tallimustine</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tallimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12062</drugbank-id>
      <name>Volasertib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Volasertib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14811</drugbank-id>
      <name>Isatuximab</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Isatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15102</drugbank-id>
      <name>Pemigatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pemigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11791</drugbank-id>
      <name>Capmatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Capmatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15685</drugbank-id>
      <name>Selpercatinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Selpercatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15699</drugbank-id>
      <name>Brexucabtagene autoleucel</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brexucabtagene autoleucel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15822</drugbank-id>
      <name>Pralsetinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pralsetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11942</drugbank-id>
      <name>Selinexor</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Selinexor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fedratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of pulmonary toxicity can be increased when Darbepoetin alfa is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00984</drugbank-id>
      <name>Nandrolone phenpropionate</name>
      <description>The therapeutic efficacy of Darbepoetin alfa can be increased when used in combination with Nandrolone phenpropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08804</drugbank-id>
      <name>Nandrolone decanoate</name>
      <description>The therapeutic efficacy of Darbepoetin alfa can be increased when used in combination with Nandrolone decanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13169</drugbank-id>
      <name>Nandrolone</name>
      <description>The therapeutic efficacy of Darbepoetin alfa can be increased when used in combination with Nandrolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05168</drugbank-id>
      <name>Vintafolide</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vintafolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vinflunine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vincamine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00012 sequence
APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA
VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS
PPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>53 °C</value>
      <source>Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.188</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.75</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>18396.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C815H1317N233O241S5</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12550</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504480</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X02158</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164743138</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01588</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000800</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Darbepoetin_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201566</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>283838</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/aranesp.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/darbepoetin-alfa-albumin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000654</id>
      <name>Erythropoietin receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1764</ref-id>
            <pubmed-id>16505108</pubmed-id>
            <citation>LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55.</citation>
          </article>
          <article>
            <ref-id>A1766</ref-id>
            <pubmed-id>17575216</pubmed-id>
            <citation>Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P19235" source="Swiss-Prot">
        <name>Erythropoietin receptor</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.</specific-function>
        <gene-name>EPOR</gene-name>
        <locus>19p13.3-p13.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>251-273</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>4.37</theoretical-pi>
        <molecular-weight>55064.725</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3416</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>EPOR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M60459</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182245</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1718</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P19235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EPOR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>EPO-R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001304|Erythropoietin receptor
MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL
ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY
EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH
KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG
SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS
AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
SDGPYSNPYENSLIPAAEPLPPSYVACS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010455|Erythropoietin receptor (EPOR)
ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT
GGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC
TTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG
GTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC
TACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT
GGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA
GAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT
GAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC
CACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC
GAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG
GGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC
CGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG
TCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG
GTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG
AAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC
AAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC
ACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG
ACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC
AGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG
CCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC
TCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT
GCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA
CTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT
GACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA
TCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG
CCCCCCAGCTATGTGGCTTGCTCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00041</identifier>
            <name>fn3</name>
          </pfam>
          <pfam>
            <identifier>PF09067</identifier>
            <name>EpoR_lig-bind</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>erythropoietin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>decidualization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>erythropoietin-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>